“The data generated to date continue to demonstrate the potential of ORIC-944 to be a best-in-class PRC2 inhibitor that may benefit a broad range of patients with prostate cancer,” said Jacob ...

Molecular characterization of myelodysplastic syndromes (MDSs) by next-generation sequencing is important in both classification and prognostic stratification of patients with lower- and ...

Polycomb getting its due at Keystone I didn?t want to give the impression from my last two posts that it?s all RNAi all the time at this year?s Keystone Symposium on Epigenetics and Chromatin ...

In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.

Cell Rep 40:111363, 2022 44. Zhang X, Murray B, Mo G, et al: The role of polycomb repressive complex in malignant peripheral nerve sheath tumor. Genes (Basel) 11:287, 2020 45. Wang Q, Montmain G, ...

Tumors of epigenetic, not genetic, origin have been demonstrated, challenging the established idea that cancer is caused only by permanent changes to DNA.

Researchers have taken a big step forward in the quest to regenerate the pancreatic beta-cells damaged by type 1 diabetes. Using FDA-approved drugs usually given to patients with rare cancers ...

Scientists believe their study represents a major contribution to chromatin and epigenetics research and has further impact in cancer studies.

Major histocompatibility complex class I (MHC-I) gene promoters are bivalently modified during development, which can be exploited in cancer cells to silence MHC-I expression and evade CD8+ T cells; ...